AFAndrew J. Frankart

Andrew J. Frankart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andrew J. Frankart has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of clinical trials addressing supportive care measures for management of acute and chronic radiation toxicities

    by Tiffany Win, Jordan Kharofa, Andrew J. Frankart

    Purpose Radiation therapy can cause acute and long-term side effects despite advances in treatment delivery techniques. While significant research has been conducted to prevent the occurrence of toxicity, there is a need for evidence-based supportive care measures to manage radiation side effects. This analysis aims to examine the current state of supportive care trials in radiation oncology and identify areas that require further study. Methods A Clinicaltrials.gov search was conducted using the term "radiation toxicity" to identify registered trials with a primary endpoint of toxicity management. These studies were further classified as supportive care interventions or toxicity prevention. Study details were evaluated for all supportive care trials. Results Of the thirty-eight supportive care trials identified, most were observational/uncategorized (50%), in phase III (28.9%), or phase II (13.2%). Head and neck (42.1%), genitourinary (18.4%), and breast (13.2%) were the most studied disease sites. Xerostomia (23.7%), mucositis (18.4%), and dermatitis (18.4%) were the most evaluated toxicities. Medication-based (28.9%), procedures (28.9%), and topical agents (21.1%) were the most common interventions. Thirty-two studies included patient-reported outcomes (PROs; 84.2%), of which seventeen trials (53.1%) had PROs as a primary endpoint. Conclusions Only a small portion of supportive care trials generate high-level evidence to evaluate interventions with patient-reported endpoints. More supportive care trials are needed to effectively manage radiation toxicities and promote compliance and long-term quality of life during and after radiation therapy. Increased funding from government and industry sponsors is required to support this research.


  • Open Access

    Durvalumab Treatment Patterns for Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Veterans Health Administration (VHA): A Nationwide, Real-World Study

    by Amanda M. Moore, Zohra Nooruddin, Kelly R. Reveles, Paromita Datta, Jennifer M. Whitehead, Kathleen Franklin, Munaf Alkadimi, Madison H. Williams, Ryan A. Williams, Sarah Smith, et al.

    Background: Durvalumab is approved for the treatment of adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This real-world study describes patient characteristics and durvalumab treatment patterns (number of doses and therapy duration; treatment initiation delays, interruptions, discontinuations, and associated reasons) among VHA-treated patients. Methods: This was a retrospective cohort study of adults with unresectable stage III NSCLC receiving durvalumab at the VHA between 1 January 2017 and 30 June 2020. Patient characteristics and treatment patterns were presented descriptively. Results: A total of 935 patients were included (median age: 69 years; 95% males; 21% Blacks; 46% current smokers; 16% ECOG performance scores ≥ 2; 50% squamous histology). Durvalumab initiation was delayed in 39% of patients (n = 367). Among the 200 patients with recorded reasons, delays were mainly due to physician preference (20%) and CRT toxicity (11%). Overall, patients received a median (interquartile range) of 16 (7–24) doses of durvalumab over 9.0 (2.9–11.8) months. Treatment interruptions were experienced by 19% of patients (n = 180), with toxicity (7.8%) and social reasons (2.6%) being the most cited reasons. Early discontinuation occurred in 59% of patients (n = 551), largely due to disease progression (24.2%) and toxicity (18.2%). Conclusions: These real-world analyses corroborate PACIFIC study results in terms of the main reasons for treatment discontinuation in a VHA population with worse prognostic factors, including older age, predominantly male sex, and poorer performance score. One of the main reasons for durvalumab initiation delays, treatment interruptions, or discontinuations was due to toxicities. Patients could benefit from improved strategies to prevent, identify, and manage CRT and durvalumab toxicities timely and effectively.